Fore Biotherapeutics
PrivateLast Round
Series D-2
Extension
Jul 7, 2026
Est. Valuation
$75M
Total Funding Raised
$249.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Fore Biotherapeutics is a biotechnology company that develops precision oncology therapies for patients with rare, unaddressed tumor mutations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fore Biotherapeutics Comparables
Compare Fore Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Erasca | 78% | |
| C4 Therapeutics | 74% | |
| Roche Holding | 72% |
Fore Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D-2 Extension | Jul 7, 2026 | ||||
| Series D | May 22, 2025 | ||||
| Series D | Aug 23, 2023 | ||||
| Series C | Sep 21, 2020 | ||||
| VC Round | Apr 30, 2018 | ||||
Series A | Jun 22, 2016 |
Fore Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series D-2 Extension |
| Samsung Securities Co., Ltd. | Series D, Series D-2 Extension |
| TaiAx Capital | Series D-2 Extension |
| Bio Capital Impact Fund | VC Round |
| Cormorant Asset Management | Series D, Series C, Series D-2 Extension |
| 3B FUTURE Health Fund | Series D, Series D-2 Extension, VC Round |
| Pontifax Venture Capital | VC Round, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 80% MoM, from 2.2K to 4K.
- Jul 7, 2026
$67M round led by Medicxi, SR One, and SymBiosis Capital Management.
Recent news
Latest coverage and updates
- attends_eventSep 11, 2026
Fore Biotherapeutics Inc. will attend event Morgan Stanley 24th Annual Global Healthcare Conference on Sep 15th '26.
- receives_financingAug 6, 2026
Fore Biotherapeutics Inc. received financing of $38M in Series D on May 1st '25.
Fore Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Fore Biotherapeutics's valuation, stock price, and market status.
Is Fore Biotherapeutics a public or private company?
Fore Biotherapeutics is a private company.
What is the current stock price of Fore Biotherapeutics?
Fore Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Fore Biotherapeutics worth (valuation)?
Fore Biotherapeutics's valuation is estimated at $75.0M based on funding round data.
Can I buy Fore Biotherapeutics stock?
Fore Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Fore Biotherapeutics's last funding round?
Fore Biotherapeutics's most recent funding round was Series D Extension on September 21, 2020.
Who are the main investors in Fore Biotherapeutics?
Key investors in Fore Biotherapeutics include OrbiMed, SR One, Medicxi.
Will Fore Biotherapeutics IPO soon?
No public IPO plans have been announced for Fore Biotherapeutics.
How can I track Fore Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Fore Biotherapeutics's secondary market activity and sign up for updates.